Levofloxacin

Generic Name
Levofloxacin
Brand Names
Levaquin, Quinsair
Drug Type
Small Molecule
Chemical Formula
C18H20FN3O4
CAS Number
100986-85-4
Unique Ingredient Identifier
RIX4E89Y14
Background

Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along w...

Indication

In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate. The oral formulation is also indicated in both adults and children 6 months of age a...

Associated Conditions
Abscesses caused by susceptible bacteria, Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible bacteria, Acute Pyelonephritis caused by Infection Due to Escherichia Coli, Bacterial Conjunctivitis caused by susceptible bacteria, Cellulitis caused by susceptible bacteria, Community Acquired Pneumonia (CAP) caused by susceptible bacteria, Furuncle caused by susceptible bacteria, Impetigo caused by susceptible bacteria, Inhalational Anthrax, Nosocomial Pneumonia caused by Pseudomonas Infections, Nosocomial Pneumonia caused by susceptible bacteria, Plague caused by Yersinia pestis, Pyoderma caused by susceptible bacteria, Wound Infections caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Chronic Bacterial prostatitis caused by susceptible bacteria, Chronic Pseudomonas Infections, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin and skin-structure infections caused by susceptible bacteria, Uncomplicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated skin and skin-structure infections caused by susceptible bacteria
Associated Therapies
-
Clinical Trials
Related News

Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy

First Posted Date
2020-08-06
Last Posted Date
2024-07-17
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
89
Registration Number
NCT04502095
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease

First Posted Date
2020-06-16
Last Posted Date
2020-08-27
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
60
Registration Number
NCT04432233
Locations
🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy

Not Applicable
Conditions
Nephrolithiasis
Interventions
Drug: Ciprofloxacin
Drug: Levofloxacin
First Posted Date
2020-05-05
Last Posted Date
2021-03-03
Lead Sponsor
Diaa Eldin Taha Ramadan Mohamed
Target Recruit Count
200
Registration Number
NCT04374188
Locations
🇪🇬

Kafrelsheikh faculty of medicine, Kafr Ash Shaykh, Kafrelsheikh, Egypt

Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)

First Posted Date
2019-12-27
Last Posted Date
2020-02-24
Lead Sponsor
Jessa Hospital
Target Recruit Count
1350
Registration Number
NCT04212403
Locations
🇧🇪

Jessa Ziekenhuis, Hasselt, Limburg, Belgium

Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin

First Posted Date
2019-10-10
Last Posted Date
2021-11-18
Lead Sponsor
Shandong University
Target Recruit Count
250
Registration Number
NCT04122287
Locations
🇨🇳

Qilu hospital, Jinan, Shandong, China

Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant

First Posted Date
2019-02-21
Last Posted Date
2024-04-23
Lead Sponsor
Henry Ford Health System
Target Recruit Count
308
Registration Number
NCT03850379
Locations
🇺🇸

Henry Ford, Detroit, Michigan, United States

Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB

First Posted Date
2019-02-04
Last Posted Date
2024-04-12
Lead Sponsor
Boston University
Target Recruit Count
220
Registration Number
NCT03828201
Locations
🇻🇳

National Lung Hospital, Hanoi, Vietnam

🇵🇭

De La Salle Health Sciences Institute, Dasmariñas, Philippines

IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis

Phase 2
Completed
Conditions
Acute Pyelonephritis
Interventions
Drug: Omadacycline
Drug: Levofloxacin
First Posted Date
2018-11-28
Last Posted Date
2020-07-07
Lead Sponsor
Paratek Pharmaceuticals Inc
Target Recruit Count
201
Registration Number
NCT03757234
Locations
🇬🇪

Site 204, Tbilisi, Georgia

🇱🇻

Site 305, Rēzekne, Latvia

🇱🇻

Site 304, Liepāja, Latvia

and more 28 locations

Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery

First Posted Date
2018-11-14
Last Posted Date
2020-07-07
Lead Sponsor
NTC srl
Target Recruit Count
125
Registration Number
NCT03740659
Locations
🇮🇹

ASST Santi Paolo e Carlo di Milano - P.O. San Paolo di Milano, Milano, MI, Italy

🇮🇹

A.O.U. Pisana - P.O. di Cisanello, Pisa, PI, Italy

Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy

First Posted Date
2018-10-17
Last Posted Date
2019-12-10
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
112
Registration Number
NCT03708848
Locations
🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy